Schizophrenia Study Finds No Significant Differences in Brain Connectivity Between Marijuana Users and Nonusers

A new brain-imaging study involving people diagnosed with schizophrenia found no significant differences in certain brain connectivity patterns between those who used marijuana and those who did not.

The study, published October 23 in the journal Schizophrenia Research, was conducted by researchers affiliated with Université Lyon 1 and other medical institutions in France, along with McGill University in Canada. The research examined whether marijuana consumption and the ratio of THC to cannabidiol (CBD) were associated with changes in brain connectivity and symptoms involving disorganized thinking.

Researchers focused on formal thought disorder, a characteristic of schizophrenia that can involve difficulties organizing thoughts, maintaining coherent speech and connecting ideas. Previous research has associated the condition with increased communication between certain brain regions, particularly the temporal gyri and striatum.

Using functional magnetic resonance imaging (fMRI), researchers examined connections between these regions in 51 patients with schizophrenia, comparing participants who consumed marijuana with those who did not. They also assessed thought disorder symptoms using a standardized psychiatric rating scale and examined whether the proportion of THC relative to CBD was associated with brain activity or symptom severity.

The results showed no statistically significant differences in the examined brain connectivity patterns between marijuana users and nonusers. Researchers also found that the THC-to-CBD ratio was not significantly associated with connectivity between the cerebral cortex and striatum or with the severity of formal thought disorder.

Beyond conventional statistical testing, the team used Bayesian analyses to evaluate the strength of evidence supporting or opposing the proposed associations. Most of these analyses produced moderate to strong evidence favoring the absence of the relationships being investigated.

The findings are notable because earlier research suggested that marijuana use, particularly products containing higher proportions of THC relative to CBD, could be associated with increased thought disorder symptoms in people with schizophrenia.

The researchers concluded that marijuana consumption was not consistently associated with altered connectivity between the examined brain regions and may not explain previously reported brain connectivity abnormalities associated with disorganized thinking.

Researchers recommended larger studies examining marijuana composition, consumption levels, dose-response relationships and different symptom categories to better understand how cannabinoid exposure may relate to brain function in people with schizophrenia.